Meet The Woman Who Launched A New Field Of Scientific Study
As a female chemical engineer, Frances Arnold was already a rarity. After all, only about 16 percent of chemical engineers are women.
But now that she has become the first woman ever to win the prestigious Millennium Technology Prize — it was awarded in Helsinki, Finland, on May 24 — Arnold is truly one of a kind.
And she knows that in addition to a big cash award (1 million euros, or about $1.3 million), the prize brings an opportunity to spotlight the gender gap in STEM (science, technology, engineering and math) careers and to be a role model for other women.
"I hope that my getting this prize will highlight...
Source: Science - The Huffington Post - May 31, 2016 Category: Science Source Type: news
Simvastatin (Oral Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 9, 2016 Category: Drugs & Pharmacology Source Type: news
Some People Really Can't Take Statins For High Cholesterol, Scientists Prove
You can't write a story about the lifesaving benefits of the cholesterol-lowering drugs called statins without getting comments like this one, from reader Bill Hayman, on my story yesterday:
I cannot take Crestor or Zetia or any form of statin drug! I can barely walk with any statin drug. My legs become painful and so weak, they feel like rubber. Several years ago, I used Lipitor and had four pancreatic attacks until I stopped the Lipitor.
Or this, from reader James Leedy:
People should be warned of side effects. Doctors should listen to patients . I have taken statins for several years. I had extreme muscle pains all t...
Source: Forbes.com Healthcare News - April 3, 2016 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
Ezetimibe/Simvastatin Post-Acute Coronary SyndromeEzetimibe/Simvastatin Post-Acute Coronary Syndrome
Can lipid-lowering therapy with ezetimibe plus simvastatin improve clinical outcomes among survivors of acute coronary syndromes? Journal of the American College of Cardiology (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 7, 2016 Category: Intensive Care Tags: Cardiology Journal Article Source Type: news
Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
issued a Complete Response Letter regarding Merck's Supplemental New
Drug Applications for ZETIA® and VYTORIN® for the reduction of the risk
of cardiovascular events (cardiovascular death, nonfatal myocardial
infarction, nonfatal stroke, hospitalization for unstable angina, or
need for revascularization) in patients with c...
Source: Merck.com - Product News - February 15, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck Receives Complete Response Letter from the U.S. FDA for ZETIA ® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
issued a Complete Response Letter regarding Merck ' s Supplemental New
...
Source: Merck.com - Product News - February 15, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
The Jekyll and Hyde of Statins
By Drs. David Niesel and Norbert Herzog, Medical Discovery News Cholesterol-lowering drugs called statins are the most prescribed drug ever. About 30 percent of Americans are currently taking statins such as Crestor, Lipitor, Mevacor and Zocor. Overall, statins can be good thing, but as with all drugs, there are some negative effects. Statins lower cholesterol by inhibiting a protein called HMG-CoA reductase. Since high cholesterol levels are linked to heart disease, statins can reduce the risks of heart attack and stroke, two of the leading causes of death in the United States. Recent reports from the American Heart Ass...
Source: Science - The Huffington Post - February 3, 2016 Category: Science Source Type: news
Impax Receives Tentative FDA Approval for Generic Version of Vytorin(R) (ezetimibe and simvastatin) Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg
HAYWARD, Calif., Feb. 2, 2016 -- (Healthcare Sales & Marketing Network) -- Impax Laboratories, Inc. (IPXL) today announced that Impax has received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application... Biopharmaceuticals, Generic, FDAImpax Laboratories, ezetimibe, simvastatin, Vytorin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 2, 2016 Category: Pharmaceuticals Source Type: news
Could a cholesterol-lowering drug be a potential treatment for Parkinson's?
A clinical trial using cholesterol-lowering treatment Simvastatin in people living with Parkinson's is getting underway in centers across England -- with the hope that it could become one of a number of effective treatments available to treat Parkinson's. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 11, 2016 Category: Science Source Type: news
Could a cholesterol-lowering drug be a potential treatment for Parkinson's?
Cholesterol-lowering drug Simvastatin trialled as a potential neuroprotective treatment for Parkinson's. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - January 11, 2016 Category: Neurology Tags: Parkinson's Disease Source Type: news
Celebratory Excess Drinking Causes Atrial Arrhythmias
It's New Year's Eve and the ball is about to drop. You and your partner respond to a party that's been going for several hours to care for a person who's dizzy. Making your way through the streamers and horns, you're ushered to a back bedroom where you're introduced to Uncle Bill.
Uncle Bill is 52 years old and lying on the bed. He looks up at you and says, "Something's not right, boys." You reach to feel his pulse and ask what he means by his statement. You note the smell of alcohol on his breath as he tells you the evening was going great until he suddenly felt faint and his heart began to race. He sat down and...
Source: JEMS Patient Care - December 22, 2015 Category: Emergency Medicine Authors: Dennis Edgerly, EMT-P Tags: Cardiac & Resuscitation Toxicology Columns Source Type: news
Merck Statement on FDA Advisory Committee Meeting on IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)
Dateline City:
KENILWORTH, N.J.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, issued today the following statement after the conclusion of a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss the results of IMPROVE-IT, an investigational study comparing treatment with VYTORIN® (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes.
Language:
Engl...
Source: Merck.com - Corporate News - December 14, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
New Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)
Dateline City:
KENILWORTH, N.J.
Further Analyses on the Long-Term Safety and Efficacy of VYTORIN® from the IMPROVE-IT Study Presented at the European Society of Cardiology (ESC) Meeting
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD in the United States and Canada, today
announced results from new analyses from the IMPROVE-IT study.
“IMPROVE-IT presents us with the opportunity to look at cardiovascular
outcomes data for patients trea...
Source: Merck.com - Research and Development News - September 1, 2015 Category: Pharmaceuticals Tags: Research and Development News Source Type: news
New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® (sitagliptin) Will Be Presented at the European Society of Cardiology Congress
Dateline City:
KENILWORTH, N.J.
Additional Real-World Analyses from DYSIS and DYSIS II Assessing the Treatment of Dyslipidemia to be Presented
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that new analyses from the investigational IMPROVE-IT
(IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial)
study of VYTORIN® (ezetimibe and simvastatin), the TECOS
(Trial Evaluating Card...
Source: Merck.com - Product News - August 20, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
Studies support broader use of cholesterol-lowering statins
The latest guidelines used to determine who should take a cholesterol-lowering statin to prevent heart disease appear to be more accurate and cost-efficient than the previous guidelines. That’s according to two studies led by Harvard researchers, both published in this week’s Journal of the American Medical Association.
For many years, the main deciding factor in who needed to take a statin was the level of an individual’s harmful low-density lipoprotein cholesterol (LDL). Updated guidelines published in 2013 by the American College of Cardiology and the American Heart Association moved away from LDL and ...
Source: New Harvard Health Information - July 16, 2015 Category: Consumer Health News Authors: Julie Corliss Tags: Drugs and Supplements cholesterol high cholesterol statins Source Type: news
